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Hepatitis C: the disease, the virus and the therapy
Up  to  170  million  people  worldwide  are  chronically 
infected with hepatitis C virus (HCV) [1]. Chronic HCV 
infection  is  asymptomatic  or  associated  with  relatively 
mild hepatitis in most individuals. However, about 20% 
of  patients  have  progressive  hepatitis,  where  disease 
proceeds from hepatitis of gradually worsening severity, 
through  increasing  hepatic  fibrosis  and  cirrhosis,  and 
eventually  terminating  in  fatal  liver  failure  or  hepato­
cellular carcinoma [2]. The rate of progression along this 
path  varies  from  a  few  years  in  exceptionally  rapid 
progressors to many decades in slow progressors, with 
relatively slow progression being the norm.
HCV  is  a  hepatotropic  flavivirus  in  the  Hepacivirus 
genus. The enveloped virion contains a positive­polarity 
RNA genome that is about 9,600 nucleotides long and 
encodes  a  polyprotein  of  roughly  3,000  amino  acids. 
Cleavage  of  the  polyprotein  produces  three  structural 
proteins  (core,  E1  and  E2)  and  seven  non­structural 
proteins (P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). 
The HCV genome is genetically very variable, with six 
genotypes that are less than 72% genetically identical, and 
over  100  subtypes  with  identities  of  75%  to  86%  [3]. 
Genotype 1 accounts for about 75% of the HCV isolates 
in the USA; almost all are subtype 1a or 1b. Independent 
HCV isolates of a given subtype typically differ by 6% to 
10%, and genetic variation between viral genomes within 
an individual is usually 1% to 3% because of the replica­
tion  of  HCV  as  a  quasispecies  (that  is,  a  collection  of 
genetic variants that clusters around a master sequence 
and that evolves as a unit [4]).
HCV infection is currently treated with a combination 
of  pegylated  IFNα  and  ribavirin.  Treatment  eliminates 
the virus (sustained viral response, SVR) in 50% to 60% of 
genotype  1  patients  [5].  Treatment  typically  lasts  for 
48 weeks, but it is discontinued if viremia is present at 
24  weeks  because  the  chances  of  achieving  SVR  are 
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© 2011 BioMed Central Ltdnegligible if the virus is detectable at this time. There are 
two major drawbacks to this therapy beyond its limited 
efficacy. First, IFNα causes severe side­effects, including 
flu­like illness, depression, anorexia, anemia and lympho­
penia, and these problems are exacerbated by ribavirin 
[6,7]. The risk of these complications is high enough that 
many  patients  are  ineligible  for  treatment.  Treatment 
therefore requires supervision by a skilled medical team, 
and  even  then  a  third  of  patients  can  be  incapable  of 
taking the full regimen without dose reductions. Second, 
therapy  can  cost  over  US$40,000  per  patient  [8],  and 
hence it is unaffordable for many patients.
Numerous  direct­acting  inhibitors  of  the  enzymes  of 
HCV are under development [9­11], and two NS3 protease 
inhibitors are likely to be approved in 2011. However, all 
direct­acting inhibitors of HCV are plagued by very rapid 
development  of  resistance  due  to  the  high  genetic 
diversity and rapid evolution of HCV, and hence the new 
drugs  will  be  used  in  combination  with  IFNα  and 
ribavirin for the foreseeable future [12].
Here,  we  review  recent  advances  in  our  knowledge 
concerning the host and viral genetic variables that affect 
outcome of therapy.
Roles of IFNα and ribavirin during therapy
IFNα provides the primary antiviral effect and can clear 
HCV when used alone, whereas ribavirin is ineffective by 
itself  but  roughly  doubles  the  viral  clearance  rate  when 
taken with IFN [5,13]. The mechanisms by which IFNα 
and ribavirin suppress HCV are incompletely under  stood, 
but each drug clearly acts through multiple mecha  nisms. 
IFNα  triggers  the  type  1  IFN  response  and  stimulates 
adaptive immune responses to the virus, but the details of 
how  these  cellular  responses  control  HCV  are  largely 
unknown. Ribavirin may act by skewing host immunity 
towards a Th1­type response, amplifying the type 1 IFN 
response,  suppressing  cellular  guanosine  tri  phos  phate 
pools,  and/or  interfering  with  the  fidelity  of  HCV 
replication. Importantly, all of these antiviral pressures are 
mediated by cellular effectors, with the exception of the 
potential impact of ribavirin on the viral RNA polymerase.
Host and viral genetic variation both affect 
outcome of therapy
The outcome of IFN­based therapy for HCV is dependent 
on the genetic systems of both the human host and the 
virus. Host genetic factors that influence the outcome of 
therapy include gender, race and variation in genes of the 
immune system. The primary viral genetic factor is the 
HCV genotype because some genotypes are more sensi­
tive  to  IFN  than  others,  but  other  aspects  of  viral 
variability are also important. The major host and viral 
genetic factors affecting outcome of therapy are summar­
ized in Figure 1.
The  human  immune  responses  to  HCV  and  the 
counter  measures  of  the  virus  are  directly  relevant  to 
antiviral therapy because the dominant drug in therapy is 
IFNα, which is a key cytokine in the type 1 IFN response. 
The  replication  of  HCV  replication  triggers  innate 
immune  pressures,  and  then  the  virus  counters  these 
immune responses with an array of immunosuppressive 
strategies  to  promote  its  persistence  [14,15].  The  best 
under  stood immunosuppressive strategies include inhi­
bi  tion of protein kinase R (PKR) by the viral NS5A and 
E2  proteins,  cleavage  of  cellular  signal  transduction 
molecules  downstream  of  the  pathogen  RNA  sensors 
RIG­I  and  TLR3  by  the  NS3/4A  protein,  and  altering 
IL12 production through secretion of the core protein; 
other less thoroughly characterized suppressive activities 
also exist.
Accurate prediction of the outcome of therapy would 
reduce  complications  associated  with  futile  treatment 
while simultaneously increasing the number of potential 
responders  who  receive  therapy.  The  pleiotropic 
pressures  applied  against  HCV  by  IFN­based  therapy 
have two key implications on pharmacogenetic personali­
za  tion  of  treatment  for  HCV.  First,  the  role  of  the 
immune system in pharmacological control of HCV indi­
cates that human genetic polymorphisms affecting these 
pathways  could  modulate  efficacy  of  therapy.  Second, 
viral  resistance  to  IFN­based  therapies  will  be  propor­
tional to the net effect of the multiple immunosuppressive 
activities of HCV. Therefore, predicting the outcome of 
therapy  will  require  integrating  the  efficacies  of  the 
immunosuppressive mechanisms of a given HCV isolate, 
and  then  interpreting  the  viral  resistance  potential  in 
context  of  the  genetic  profile  of  the  patient  at  loci 
associated with outcome of treatment.
Host genetic associations with outcome of therapy
The  dominant  role  of  the  immunomodulator  IFNα  in 
treating HCV infection has driven an extensive search for 
genetic associations between components of the immune 
system and outcome of therapy [16­18] (Table 1). Many 
studies have focused on the human leukocyte antigen class 
I and II genes, and most, but not all, studies have found 
associations  between  particular  alleles  and  out  come  of 
IFN­based therapy. However, there is little overlap in the 
alleles  identified  by  the  various  groups.  Genetic  asso­
ciations with outcome of therapy have also been reported 
for the genes encoding KIR2DL5, IL6, IL10, IL12B, CCL5, 
TGFβ,  TNFα,  IFNγ,  osteopontin,  GNB3,  and  CTLA4. 
However,  other  studies  have  failed  to  find  associations 
with  many  of  these  genes.  The  incon  sistencies  in  these 
data appear to be due to differences among the studies in 
the  racial  make­up  and  HIV  co­infection  status  of  the 
cohorts, the definition of thera  peutic response, the therapy 
employed  (IFNα  monotherapy,  IFN  plus  ribavirin,  or 
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infecting  the  study  participants.  Together,  these  data 
clearly  demonstrate  that  polymorphisms  in  immune 
system genes can strongly influence the outcome of anti­
HCV therapy, but these associations appear to be context 
dependent, and hence are unlikely to be broadly useful in 
predicting treatment outcome.
A breakthrough in understanding human genetic asso­
ciations with outcome of therapy occurred in 2009 when 
three seminal genome­wide association studies demon­
strated that polymorphisms near the IL28B gene, which 
encodes IFNλ3 [19], were strongly associated with treat­
ment outcome for HCV genotype 1 [20­22]. The strongest 
association was found for SNP rs12979860, located about 
3 kb upstream of the IL28B coding region. Patients with a 
CC genotype at this SNP were more than twice as likely 
to achieve SVR as patients with a CT or TT genotype 
[20]. The three studies each identified different SNPs near 
IL28B,  but  the  underlying  biological  association  with 
treatment outcome appears to be the same because there 
is  a  strong  linkage  disequilibrium  among  these  SNPs. 
Suppiah et al. [21] estimated that the cumulative effect of 
the favorable allele at the IL28B locus is to increase SVR 
by  32%  relative  to  a  population  in  which  the  allele  is 
absent (population attributable risk). The favorable asso­
ciation of the CC genotype was found in patients of both 
European and African­American descent, and differential 
prevalence of the CC genotype explained approximately 
half  of  the  twofold  poorer  response  rate  to  treatment 
found in African Americans [20,23].
The effect of variation at r12979860 with HCV treat­
ment outcome has been validated in a new cohort that 
included 186 genotype 1 and 45 genotype 2 or 3 patients 
[24]. The r12979860 SNP has also been associated with 
more rapid decline of viral titers during therapy and with 
end­of­treatment response [25]. An association of the CC 
genotype at the r12979860 SNP with SVR is also found in 
patients infected with the easier­to­treat HCV genotypes 
2 or 3, but only in patients who do not have a rapid early 
decline  in  HCV  titers  [26].  The  association  of  IL28B 
polymorphisms and response to treatment also appears 
to hold in patients that are co­infected with HIV [27­29]. 
A  similar  association  of  polymorphisms  in  the  IL28B 
r12979860 SNP is found with spontaneous clearance of 
acute genotype 1 HCV infection [30­32], and with a differ­
ent SNP for patients infected with genotype 1 or 4 for both 
spontaneous clearance and response to therapy [33].
The  IL28B  gene  encodes  the  type  3  IFN,  IFNλ  [19]. 
IFNλ has been shown to inhibit HCV replication [34], so 
the variations in the IL28B gene mutations presumably 
affect the efficacy of the innate immune response against 
HCV during therapy. Regardless of mechanism, the very 
strong  association  of  the  IL28B  polymorphisms  with 
outcome of IFN­based therapy has already led to clinical 
genetic tests to help guide antiviral treatment.
The association of human SNPs with ribavirin­induced 
reduction  in  hemoglobin  levels  has  also  been  assessed 
[35] because treatment­induced hemolytic anemia is one 
of the most serious side­effects of IFN­based therapy [7]. 
This does not directly address treatment outcome, but 
anemia often causes dose reductions that lower treatment 
efficacy.  Genotypes  of  SNPs  rs1127354  and  rs7270101 
within the inosine triphosphatase gene that decrease the 
activity of the enzyme have been found to be strongly 
Figure 1. Prominent host and viral genetic factors that influence the outcome of IFN-based therapy for HCV. The best-documented host 
genetic factors that favor viral clearance and HCV factors that promote viral survival during therapy are indicated. HLA, human leukocyte antigen; 








Race: Asian or Caucasian
Interferon λ: IL28B SNPs (rs12979860 CC and others)
Side effect control: ITPA low activity alleles
Antigen recognition: context-dependent HLA class I and II
Immune modulation: context-dependent cytokine alleles
Virus
Genotype: genotype 1a, 1b
Inter-patient variability: similarity to population-wide consensus sequence
Quasispecies variability: stable during therapy
Core variations: non-consensus sequences at subtype 1b residues 70 and/or 91
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results  were  confirmed  in  an  independent  cohort  of 
western patients [36]. Two additional studies confirmed 
the  association  of  rs1127354,  but  not  rs7270101,  with 
Table 1. Host genetic factors that affect treatment outcome
Gene symbol  Gene name/description  Polymorphism  Effect on treatment  Reference(s)
IFNλ      
  IL28B  Interferon, λ3   SNP rs12979860 (C/C)  Twofold increased rate of SVR  [20]
  IL28B  Interferon, λ3  SNPs rs8099917 (G)    Associated with non-response   [22]
      and rs12980275
  IL28B  Interferon, λ3  SNP rs809917 (T)  Twofold increased rate of SVR  [21]
Side-effect modulator       
  ITPA  Inosine triphosphatase  SNPs rs1127354 (A)   Increased protection against  [35-38]
      and rs7270101 (C)  ribavirin-induced anemia
HLA alleles       
  HLA-A24-B54-DR4  HLA class I/II haplotype  NA  Associated with non-response   [73]
  HLA-B54  HLA class I allele  NA  Associated with non-response  [73]
  HLA-DRB1*0404  HLA class II allele  NA  Associated with response  [74]
  HLA-DRB1*0701, -DRA1*0201, -DQB1*02  HLA class II haplotype  NA  Associated with response  [75]
  HLA-A11, -B51, -CW5 and -DRB1*15  HLA class I and II alleles  NA  Associated with response  [76]
  HLA-A24  HLA class I allele  NA  Associated with non-response  [76]
  HLA-DRB1*04  HLA class II allele  NA  Associated with non-response   [77]
        to IFN monotherapy
  HLA-DRB1*07  HLA class II allele  NA  Associated with response  [78]
  HLA-A33  HLA class I allele  NA  Associated with response  [79]
  HLA-DRB1*07  HLA class II allele  NA  Associated with non-response  [80]
  HLA-DRB1*11, -DRB1*0301  HLA class II alleles  NA  Associated with response  [80]
  HLA-A24, -B40 -B46  HLA class II alleles  NA  Associated with response  [81]
Other immune-related genes       
  KIR2DL5   Killer cell immunoglobulin-  NA  Associated with non-response   [82]
    like receptor
  IL6  Interleukin 6  IL6 C174G  Associated with response  [83]
  IL10  Interleukin 10  IL10 -592A and -819T  Associated with response  [84,85]
  IL12B  Interleukin 2B  IL12B 3’-UTR 1188C  Associated with response   [86]
  MXA  Interferon-inducible protein  MXA -88G and -123A  Response to IFN monotherapy  [87]
  CCR5  Chemokine receptor 5  CCR5 -Δ32  Associated with non-response to   [88]
        IFN monotherapy
  CCL5  Chemokine ligand 5, RANTES  CCL5 Int1.1C and   Associated with non-response  [89]
      3’ 222C
  TGFβ  Transforming growth factor β  TGFβ 10T/T, 25G/G   High producer TGFβ genotype  [90]
      and 10T/C, 25 G/G  associated with response
  TNFα  Tumor necrosis factor α  TNFα -308A  Associated with response  [91]
  IFNγ  Interferon γ  IFNγ -764G  Associated with response  [92]
  OPN  Osteopontin  OPN -1748G/G or G/A
OPN -443 T/T  Associated with response  [93]
  GNB3  Guanine nucleotide-binding   GNB3 825 C/C  Associated with non-response  [94,95]
    protein β polypeptide 3
  CTLA4  Cytotoxic T-lymphocyte   CTLA4 -318C -49G  Associated with response  [96,97]
    associated protein, T-cell   haplotype 
    inhibition
HLA, human leukocyte antigen; IFN, interferon; NA, not applicable; SNP, single-nucleotide polymorphism; SVR, sustained viral response; UTR, untranslated region.
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with HCV genotype 1b [37,38]. Sakamoto et al. [37] also 
found that patients with the favorable inosine tri  phos­
phatase  allele  have  a  higher  rate  of  SVR,  which  they 
attribute to better adherence to therapy.
Viral genetic associations with outcome of 
IFN‑based therapy
The clearest indication that the high genetic variation of 
HCV affects outcome of therapy is that patients infected 
with  genotype  1  achieve  SVR  about  50%  of  the  time 
follow  ing  48  weeks  of  therapy,  whereas  patients  with 
genotypes 2 and 3 achieve SVR with frequencies >80% 
after only 24 weeks of treatment [5]. HCV genotype is 
therefore a key parameter in deciding whether to initiate 
treatment, with a higher proportion of patients infected 
with genotype 2 and 3 being eligible for treatment.
A  fundamental  aspect  of  the  biology  of  HCV  is  its 
replication  as  a  quasispecies.  The  influence  of  quasi­
species  diversity/complexity  on  efficiency  of  antiviral 
therapy has been extensively explored, with conflicting 
results.  Better  responses  have  been  linked  to  low 
pretreatment  quasispecies  diversity/complexity  in  most 
studies [39­42] but not in others [43,44]. The reasons for 
this discrepancy are not fully understood. In contrast, a 
rapid  shift  of  the  quasispecies  spectrum  early  during 
treat  ment  is  clearly  associated  with  better  response 
[45,46]. In an attempt to clarify the role of HCV quasi­
species variation in viral sensitivity to IFN­based therapy, 
we  evaluated  the  association  of  baseline  HCV  quasi­
species diversity/complexity in the hypervariable region 
1 of the E2 protein with response to therapy in 153 HCV 
genotype 1 patients and found that quasispecies diversity/
complexity can affect the outcome of therapy, but that 
this effect may become apparent only when the diversity/
complexity rises above a critical point [47].
Variations in the quasispecies master sequence (defined 
in practical terms as the consensus HCV sequence within 
a patient) between individuals have also been associated 
with outcome of therapy. The first such observation was 
that the number of variations in subtype 1b amino acid 
residues 2209 to 2248 (the ‘interferon sensitivity deter­
min  ing  region’,  ISDR)  relative  to  HCV  strain  J  was 
correlated with response to IFN­based therapy [48]. The 
ISDR is part of a PKR­binding site [15], and consequently 
this  association  is  based  on  a  reasonable  mechanism: 
differential  inhibition  of  PKR  activity  by  variant  HCV 
genomes. The association of variability in the ISDR with 
non­response  has  been  consistently  found  in  Japanese 
patients infected with subtype 1b, but is weak in other 
contexts [49,50]. The sequence at the ISDR remains an 
independent predictor of outcome for Japanese genotype 
1b patients even when normalized for the effect of IL28B 
polymorphisms [51,52].
Variation at HCV core protein positions 70 and/or 91 
relative to the prototype sequences of R70 and L90 has 
been  repeatedly  associated  with  non­response  to  IFN­
based therapy in Japanese genotype 1b patients [53­55], 
but in not in genotype 2a patients [56]. Variation at core 
residues 70 and/or 91 in HCV 1b patients has remained a 
predictor of treatment outcome in multivariate models 
including  the  IL28B  polymorphisms  [57]  and  during 
triple  therapy  including  IFN,  ribavirin  and  one  of  the 
promising NS3 protease inhibitors [58].
Similarly, genetic variation at a PKR­binding site in the 
viral E2 protein, termed the PePHD, has been associated 
with response to therapy in a few studies [59,60], but not 
in most [61,62].
This association of low viral genetic diversity relative to 
the  population­wide  consensus  sequence  with  poor 
response to therapy implies that viral sequences with low 
diversity are closest to an optimal sequence and hence 
have  the  greatest  IFN­resistance  potential.  In  this 
context, resistance can be impaired by variations at many 
different  sites  throughout  the  viral  genome.  However, 
results from the various HCV genetic studies have often 
been incompletely reproducible, possibly due to comple­
mentation  between  the  multiple  immunosuppressive 
activities of HCV that would not have been evident in 
analysis of individual viral genes. This appears to be the 
case because analysis of the full HCV coding potential 
revealed  that  the  viral  genomes  in  responders  to  IFN­
based therapy are much more diverse than genomes from 
non­responders,  that  these  diversity  differences  are 
concentrated in genes with known immunosuppressive 
activities (especially the core, E2, NS3 and NS5A genes), 
and that an individual isolate may not necessarily have 
the same diversity pattern at all of these genes [63­65]. 
Our  very  rough  estimate  is  that  differences  in  HCV 
genetic diversity among infected individuals may account 
for about 30% of the treatment failures [65]; this fraction 
is similar to that contributed by variation in the human 
IL28B locus [21].
The  potential  for  intragenomic  complementation  is 
emphasized by the recently discovered genome­wide hub­
and­spoke networks of amino acid covariances in HCV 
[66,67]. The structure of these networks indicates that the 
viral genome functions as an integrated unit. Therefore, we 
asked whether the networks could improve prediction of 
therapeutic efficacy through their ability to integrate infor­
mation across the viral genome. The co  variance networks 
were  found  to  be  very  different  in  sequences  from 
responders and non­responders to IFN­based therapy, and 
differences in the networks could help predict outcome of 
therapy in this set of samples [66]. This result has not been 
independently  confirmed  because  there  are  no  other 
publicly available full­ORF HCV sequences from patients 
for whom the outcome of IFN­based therapy is known.
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pharmacogenetic tailoring of therapy
Antiviral therapy for HCV will change dramatically in the 
near future as direct­acting antiviral drugs targeting the 
viral  protease  and  RNA  polymerase  activities  become 
available  [9­11].  These  compounds  cannot  be  used  as 
monotherapies because resistance develops within weeks 
when they are used alone [12,68­70], so at least the first 
generation of direct­acting drugs will be used in combi­
nation  with  IFNα  and  ribavirin.  Therefore,  pharmaco­
genetic  personalization  of  HCV  therapy  will  soon  add 
assessment  of  viral  resistance  mutations  to  the  direct­
acting agents to evaluation of host and viral markers of 
IFN efficacy. Evaluation of the resistance markers will be 
similar to what is currently done for HIV and hepatitis B 
virus [71,72]. As the anti­HCV pharmacological toolbox 
increases,  the  viral  markers  governing  efficacy  of  the 
direct­acting  antivirals  will  become  progressively  more 
important for guiding the choice of drugs to be employed. 
Eventually,  a  cocktail  of  direct­acting  compounds  is 
expected to eliminate the need for IFN entirely. When 
this  happens,  the  role  of  host  immunological  poly­
morphisms and immunosuppressive genetic patterns of 
HCV in predicting therapeutic efficacy will be supplanted 
by assessment of viral variables that define the sensitivity 
of  a  given  HCV  isolate  to  the  drugs.  A  role  for  host 
markers  in  guiding  therapy  may  persist,  but  it  will  be 
limited to evaluation of sensitivity to side­effects of the 
drugs. Although many promising anti­HCV drugs are in 
the pipeline, it is impossible to predict when IFN will be 
supplanted,  and  so  pharmacogenetic  prediction  of  the 
response of HCV to therapy will remain a dynamic field 
for the foreseeable future.
Conclusions
HCV infections are a leading cause of liver disease and 
liver  cancer  worldwide.  HCV  infection  is  treated  with 
IFNα plus ribavirin, but this expensive, year­long therapy 
is plagued with severe side­effects and it clears the virus 
in only about half of patients. Response of HCV to IFN­
based therapy is affected by variations in human genes 
controlling  antiviral  immune  responses  and  by  differ­
ences  in  HCV  genes  that  suppress  these  immune 
responses. The most prominent human genetic associa­
tions with outcome of therapy are polymorphisms within 
the IL28B gene, but associations with variations in the 
human leukocyte antigen and cytokine genes also exist. 
Obtaining a molecular understanding of the mechanisms 
by  which  these  genetic  associations  modulate  the  out­
come  of  therapy  would  substantially  improve  therapy. 
The most obvious viral genetic association is that HCV 
genotype 1 is less sensitive to treatment than are geno­
types 2 and 3, but genetic differences at the isolate and 
quasispecies  levels  also  affect  outcome  of  therapy. 
Understanding  the  mechanisms  underlying  these  viral 
genetic  associations  would  also  improve  therapeutic 
options for HCV patients. The contribution of both host 
and viral genetic variations in determining the outcome 
of  therapy  indicates  that  predicting  the  outcome  of 
therapy for HCV will require integrating the efficacies of 
the  immunosuppressive  mechanisms  of  a  viral  isolate, 
and  then  interpreting  the  viral  resistance  potential  in 
context  of  the  genetic  profile  of  the  patient  at  genes 
associated with outcome of therapy. Reaching this goal 
will  require  a  deeper  understanding  than  is  currently 
available of the human and viral genetic associations with 
response to therapy and of how these genetic variations 
interact with each other. Anti­HCV therapy is expected 
to  change  dramatically  in  the  near  future  with  the 
approval of direct­acting inhibitors of viral proteins, so 
outcome prediction will soon need to incorporate viral 
genetic  markers  of  the  resistance  of  HCV  to  the  new 
drugs. This will require detailed viral genetic analyses to 
identify clinically relevant resistance mutations and their 
cross­resistance  characteristics.  Eventually  the  direct­
acting drugs are expected to eliminate the need for IFN 
and ribavirin. At this time, evaluation of human genetic 
markers of immunological efficacy and viral markers of 
immunosuppressive  potential  will  be  supplanted  by 
assessment of viral biomarkers of drug sensitivity.
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